Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis

References

1. 1.↵
   2. Frohman EM,
   3. Racke MK,
   4. Raine CS

   . Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006;354:942–55 doi:10.1056/NEJMra052130 pmid:16510748

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Nelson LM,
   2. Tanner CM,
   3. Van Den Eeden SK, et al.

   2. Ascherio A,
   3. Munger K

   . Multiple sclerosis. In: Nelson LM, Tanner CM, Van Den Eeden SK, et al., eds. Neuroepidemiology: From Principles to Practice. New York: Oxford University Press; 2004:188–222
3. 3.↵
   2. Ramagopalan SV,
   3. Dobson R,
   4. Meier UC, et al

   . Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9:727–39 doi:10.1016/S1474-4422(10)70094-6 pmid:20610348

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Marrie R,
   3. Rudick R,
   4. Horwitz R, et al

   . Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041–47 doi:10.1212/WNL.0b013e3181d6b125 pmid:20350978

   Abstract/FREE Full Text
5. 5.↵
   2. Marrie RA,
   3. Reider N,
   4. Cohen J, et al

   . A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler 2015;21:282–93 doi:10.1177/1352458514564490 pmid:25533299

   Abstract/FREE Full Text
6. 6.↵
   2. Marrie RA,
   3. Reider N,
   4. Cohen J, et al

   . A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015;21:318–31 doi:10.1177/1352458514564485 pmid:25533300

   Abstract/FREE Full Text
7. 7.↵
   2. Marrie RA,
   3. Reider N,
   4. Cohen J, et al

   . A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler 2015;2:342–49 doi:10.1177/1352458514564486 pmid:25533301

   CrossRefPubMed
8. 8.↵
   2. Marrie RA,
   3. Reider N,
   4. Stuve O, et al

   . The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. Mult Scler 2015;21:332–41 doi:10.1177/1352458514564488 pmid:25538150

   Abstract/FREE Full Text
9. 9.↵
   2. Marrie RA,
   3. Reider N,
   4. Cohen J, et al

   . The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler 2015;21:305–17 doi:10.1177/1352458514564487 pmid:25583845

   Abstract/FREE Full Text
10. 10.↵
    2. Marrie RA,
    3. Yu BN,
    4. Leung S, et al

    ; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler 2012;18:1310–19 doi:10.1177/1352458512437814 pmid:22328682

    Abstract/FREE Full Text
11. 11.↵
    2. Marrosu MG,
    3. Cocco E,
    4. Lai M, et al

    . Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 2002;359:1461–65 doi:10.1016/S0140-6736(02)08431-3 pmid:11988243

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Tettey P,
    3. Simpson S Jr.,
    4. Taylor BV, et al

    . Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci 2014;347:23–33 doi:10.1016/j.jns.2014.10.020 pmid:25454639

    CrossRefPubMed
13. 13.↵
    2. Tremlett HL,
    3. Evans J,
    4. Wiles CM, et al

    . Asthma and multiple sclerosis: an inverse association in a case-control general practice population. QJM 2002;95:753–56 doi:10.1093/qjmed/95.11.753 pmid:12391388

    Abstract/FREE Full Text
14. 14.↵
    2. Ramagopalan SV,
    3. Dyment DA,
    4. Herrera BM, et al

    . Clustering of autoimmune disease in families at high risk for multiple sclerosis? Lancet Neurol 2007;6:206–07; author reply 207 pmid:17303524

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Marrie RA

    . Psychiatric comorbidity in multiple sclerosis: it's not the genes. Mult Scler 2014;20:1803–05 doi:10.1177/1352458514543344 pmid:25520402

    FREE Full Text
16. 16.↵
    2. Ramagopalan SV,
    3. Dyment DA,
    4. Valdar W, et al

    ; Canadian Collaborative Study Group. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007;6:604–10 doi:10.1016/S1474-4422(07)70132-1 pmid:17560172

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Marrosu MG,
    3. Motzo C,
    4. Murru R, et al

    . The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. Hum Mol Genet 2004;13:2919–24 doi:10.1093/hmg/ddh319 pmid:15471889

    Abstract/FREE Full Text
18. 18.↵
    2. Zorzon M,
    3. Zivadinov R,
    4. Nasuelli D, et al

    . Risk factors of multiple sclerosis: a case-control study. Neurol Sci 2003;24:242–47 doi:10.1007/s10072-003-0147-6 pmid:14658040

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Daniels GH,
    3. Vladic A,
    4. Brinar V, et al

    . Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80–89 doi:10.1210/jc.2013-2201 pmid:24170099

    CrossRefPubMed
20. 20.↵
    2. Gold R,
    3. Montalban X

    . Multiple sclerosis: more pieces of the immunological puzzle. Lancet Neurol 2012;11:9–10 doi:10.1016/S1474-4422(11)70268-X pmid:22172612

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Kozovska ME,
    3. Hong J,
    4. Zang YC, et al

    . Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999;53:1692–97 doi:10.1212/WNL.53.8.1692 pmid:10563614

    Abstract/FREE Full Text
22. 22.↵
    2. Simpson CR,
    3. Anderson WJ,
    4. Helms PJ, et al

    . Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology: a population-based study using computerized general practice data. Clin Exp Allergy 2002;32:37–42 doi:10.1046/j.0022-0477.2001.01250.x pmid:12002734

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Edwards LJ,
    3. Constantinescu CS

    . A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 2004;10:575–81 doi:10.1191/1352458504ms1087oa pmid:15471376

    Abstract/FREE Full Text
24. 24.↵
    2. Zivadinov R,
    3. Cox JL

    . Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007;79:449–74 doi:10.1016/S0074-7742(07)79020-7 pmid:17531854

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Weinstock-Guttman B,
    3. Zivadinov R,
    4. Horakova D, et al

    . Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013;84:1186–91 doi:10.1136/jnnp-2012-304740 pmid:23595944

    Abstract/FREE Full Text
26. 26.↵
    2. Zivadinov R,
    3. Weinstock-Guttman B,
    4. Hashmi K, et al

    . Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009;73:504–10 doi:10.1212/WNL.0b013e3181b2a706 pmid:19687451

    Abstract/FREE Full Text
27. 27.↵
    2. Polman CH,
    3. Reingold SC,
    4. Edan G, et al

    . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840–46 doi:10.1002/ana.20703 pmid:16283615

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Weinstock-Guttman B,
    3. Jacobs LD,
    4. Brownscheidle CM, et al

    ; New York State Multiple Sclerosis Consortium. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003;9:293–98 doi:10.1191/1352458503ms909oa pmid:12814178

    Abstract/FREE Full Text
29. 29.↵
    2. Zivadinov R,
    3. Rudick RA,
    4. De Masi R, et al

    . Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–47 doi:10.1212/WNL.57.7.1239 pmid:11591843

    Abstract/FREE Full Text
30. 30.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89 doi:10.1006/nimg.2002.1040 pmid:12482100

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Zivadinov R,
    3. Heininen-Brown M,
    4. Schirda CV, et al

    . Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59:331–39 doi:10.1016/j.neuroimage.2011.07.045 pmid:21820063

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Benjamini Y,
    3. Drai D,
    4. Elmer G, et al

    . Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279–84 doi:10.1016/S0166-4328(01)00297-2 pmid:11682119

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Fox RJ,
    3. Miller DH,
    4. Phillips JT, et al

    ; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087–97 doi:10.1056/NEJMoa1206328 pmid:22992072

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Ponsonby AL,
    3. Dwyer T,
    4. van der Mei I, et al

    . Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life. Clin Exp Immunol 2006;146:463–70 doi:10.1111/j.1365-2249.2006.03235.x pmid:17100766

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Makhlouf K,
    3. Weiner HL,
    4. Khoury SJ

    . Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs 2002;16:1–8 pmid:11772115

    PubMedWeb of Science
36. 36.↵
    2. Vaidya B,
    3. Kendall-Taylor P,
    4. Pearce SH

    . The genetics of autoimmune thyroid disease. J Clin Endocrinol Metab 2002;87:5385–97 doi:10.1210/jc.2002-020492 pmid:12466323

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Barkhof F,
    3. Calabresi PA,
    4. Miller DH, et al

    . Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5:256–66 doi:10.1038/nrneurol.2009.41 pmid:19488083

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Buckle GJ

    . Functional magnetic resonance imaging and multiple sclerosis: the evidence for neuronal plasticity. J Neuroimaging 2005;15:82S–93S doi:10.1177/1051228405284093 pmid:16385021

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Pelletier J,
    3. Audoin B,
    4. Reuter F, et al

    . Plasticity in MS: from functional imaging to rehabilitation. Int MS J 2009;16:26–31 pmid:19413923

    PubMed
40. 40.↵
    2. Strasser-Fuchs S,
    3. Enzinger C,
    4. Ropele S, et al

    . Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Mult Scler 2008;14:205–11 pmid:17986507

    Abstract/FREE Full Text